Category: Trade Association

Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines

In Pharma Industry, Trade AssociationApril 21, 2022689 Views

Six HIV/AIDS and viral hepatitis advocacy groups issued a joint statement criticizing AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

UPDATE Thursday, April 21, 2022, 5:00 p.m. EDT—AbbVie issued this statement: AbbVie supports the 340B program and is committed to the program’s goal of improving access to medicines for uninsured and vulnerable patients. Our 340B initiative does not block access

…

Lilly Providing Refunds for 340B Overcharges During Q3 2019

In Federal, Pharma Industry, Regulatory, Trade AssociationApril 12, 2022282 Views

Tom Mirga

Drug company Lilly is providing refunds for 340B overcharges on 14 NDCs during 3Q 2019.

Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the

…

Drug Makers’ 340B Pricing Restrictions Hit Small Rural Hospitals Especially Hard, Survey Shows

In Research/Reports, Trade AssociationApril 12, 2022353 Views

Tom Mirga

About two thirds (64%) of CAHs and one third (33%) of larger, more urban hospitals say their ability to keep their doors open would be affected if drug company 340B contract pharmacy restrictions become more widespread.

Small rural hospitals have lost on average 39% of their 340B contract pharmacy savings due to drug manufacturers’ conditions on 340B pricing while larger, mostly urban hospitals have lost on average 23%, a hospital group’s member survey shows.

The finding

…

Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy

In Pharma Industry, Trade AssociationApril 5, 2022795 Views

Tom Mirga

Gilead told NACHC in a letter yesterday it is concerned about the group's criticism of the company's new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity

…

340B Advocacy Group Expresses Concern About Apparent Unique Feature in J&J’s Contract Pharmacy Policy

In Pharma Industry, Trade AssociationMarch 31, 20221010 Views

Tom Mirga

Janssen Pharmaceutical companies of Johnson&Johnson outdoor sign

RWC-340B says Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently applies also to hospitals’ non-340B-purchased “own use” drugs.

Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.

J&J has not responded

…

Ryan White 340B Clinic Association Names New Managing Director

In Trade AssociationMarch 29, 2022252 Views

Tom Mirga

Trent Smith is the new Managing Director of Ryan White Clinics for 340B Access.

Ryan White Clinics for 340B Access (RWC-340B) and its management services consultant have chosen Trent Smith, a former manager and director in both the nonprofit and for-profit sectors, to be RWC-340B’s new managing director.

RWC-340B announced the hiring last week.

…

Exclusive: Leading Health Center Organization Calls Gilead’s New 340B Contract Pharmacy Restrictions “Unconscionable”

In News Alert, Pharma Industry, Trade AssociationMarch 21, 20221398 Views

Tom Mirga

NACHC called Gilead's 340B pricing conditions on Vosevi and three of its other hepatitis C drugs "the latest example of corporate greed from a pharmaceutical company."

The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from

…

Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy

In Pharma Industry, Trade AssociationMarch 17, 2022804 Views

Tom Mirga

Harvoni is one of the four hepatitis C drugs that will face restrictions under Gilead's new 340B contract pharmacy policy.

HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

Ryan White Clinics for 340B Access (RWC-340B) said

…

Non-Hospital 340B Entities Form Group to Fight on Their Own Behalf at National and State Levels

In Federal, Judicial, Legislative, Regulatory, State, Trade AssociationMarch 8, 2022796 Views

Tom Mirga

The new non-hospital 340B covered entity group 340B Grantees says its work will include outreach, education, lobbying, and litigation.

Non-hospital 340B covered entities have formed a group called 340B Grantees to fight on their own behalf on legislation, in courts, and perhaps in politics at the federal and state levels.

340B Grantees hasn’t formally announced itself yet and is

…

340B Stakeholders Congratulate Egwim on Being Named OPA Director

In Federal, Pharma Industry, Regulatory, Trade AssociationMarch 1, 2022604 Views

Tom Mirga

340B stakeholders congratulated U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as director of the office in HRSA that runs the 340B drug pricing program.

340B provider and drug industry stakeholders joined yesterday in congratulating U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as Director of the U.S. Office of Pharmacy Affairs, the federal agency that runs the 340B drug pricing program.

…

News Alert

Site Footer